Direct Binding of the Signal-transducing Adaptor Grb2 Facilitates Down-regulation of the Cyclin-dependent Kinase Inhibitor p27Kip1*

Yoriko Sugiyama, Kiichiro TomodaDagger, Toshiaki Tanaka, Yukinobu Arata, Noriko Yoneda-Kato, and Jun-ya Kato§

From the Graduate School of Biological Sciences, Nara Institute of Science and Technology, 8916-5 Takayama, Ikoma, Nara 630-0101, Japan

Received for publication, November 30, 2000, and in revised form, December 28, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Ectopic expression of Jab1/CSN5 induces specific down-regulation of the cyclin-dependent kinase (Cdk) inhibitor p27 (p27Kip1) in a manner dependent upon transportation from the nucleus to the cytoplasm. Here we show that Grb2 and Grb3-3, the molecules functioning as an adaptor in the signal transduction pathway, specifically and directly bind to p27 in the cytoplasm and participate in the regulation of p27. The interaction requires the C-terminal SH3-domain of Grb2/3-3 and the proline-rich sequence contained in p27 immediately downstream of the Cdk binding domain. In living cells, enforcement of the cytoplasmic localization of p27, either by artificial manipulation of the nuclear/cytoplasmic transport signal sequence or by coexpression of ectopic Jab1/CSN5, markedly enhances the stable interaction between p27 and Grb2. Overexpression of Grb2 accelerates Jab1/CSN5-mediated degradation of p27, while Grb3-3 expression suppresses it. A p27 mutant unable to bind to Grb2 is transported into the cytoplasm in cells ectopically expressing Jab1/CSN5 but is refractory to the subsequent degradation. These findings indicate that Grb2 participates in a negative regulation of p27 and may directly link the signal transduction pathway with the cell cycle regulatory machinery.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The proliferation of mammalian cells is strictly regulated by extracellular signals, which largely exert their effects during the G1 phase of the cell cycle. Among G1 regulatory factors, the Cdk inhibitor p27 (p27Kip1), which negatively regulates cell proliferation, is the downstream target of mitogen-stimulated signal transduction, and modulation of p27 activity is one of the most important steps not only in the control of mammalian cell proliferation but also in the regulation of normal tissue development and in the suppression of malignant transformation (1, 2). The expression level of p27 is regulated in several ways, among which cell cycle-dependent and substrate-specific proteolysis seems to be the most important (1, 2). Down-regulation of p27 has been reported to involve (i) phosphorylation of the Thr187 residue by the cyclin E-Cdk2 complex (3, 4), (ii) transport from the nucleus to the cytoplasm (5), (iii) ubiquitination mediated by the ubiquitin ligase SCFSKP2 complex (6-8), and (iv) proteolysis by the 26 S proteasome. However, the precise biochemical link between these events and the biochemical reaction that initiates p27 degradation remains to be clarified.

Recently, we have isolated a new regulator of p27, Jab1/CSN5 (5). Jab1/CSN5 was originally identified as a coactivator of c-Jun transcription factor (9), and recent findings indicate that Jab1/CSN5 is the fifth component of the COP9 signalosome complex (10) (the nomenclature of the eight subunits is now unified as CSN1-8 (11)). Although the COP9 signalosome was originally identified in Arabidopsis as a negative regulator of photomorphogenesis, purification of the COP9 signalosome complex from mammalian cells has revealed that its function is not necessarily restricted to light/dark-mediated signal transduction in plants. Genetic analysis has demonstrated that the complex plays a pivotal role in the regulation of early development (12), but the specific biochemical functions of the complex are not fully clarified yet. Jab1/CSN5 directly interacts with p27 in vitro as well as in vivo. In cells expressing ectopic Jab1/CSN5, p27 is exported from the nucleus to the cytoplasm and is induced to be degraded in a manner sensitive to chemical inhibitors of CRM1-dependent nuclear export and the 26 S proteasome. Jab1/CSN5 overexpression enables mouse fibroblasts to progress from G0 to S phase in low serum, indicating that Jab1/CSN5 plays an important role in G1 progression and cell proliferation (5).

Many growth factor receptors exhibit tyrosine kinase activity triggered by oligomerization upon binding to their specific ligands, leading to autophosphorylation (13). Phosphotyrosine residues contained in the activated receptor serve as docking sites for a variety of downstream effector molecules such as Grb2. Grb2 functions as an adaptor and contains two types of interaction domains, SH2 and SH3 (14). SH2 mediates binding to phosphotyrosine residues contained in the receptor, and SH3 directs Grb2 to the proline-rich motif, through which Grb2 associates with SOS, resulting in activation of Ras protein. The mitogen-activated protein kinase cascade consisting of Raf kinase, mitogen-activated protein kinase kinase, and mitogen-activated protein kinase (Erk1 and Erk2) as well as another Ras target, phosphatidylinositol 3-kinase, acts downstream of Ras and facilitates cell cycle progression through G1. Introduction of a dominant negative form of Ras into proliferating cells up-regulates p27 protein expression (15, 16), while activation of Ras induces p27 down-regulation (17). Moreover, pharmacological inhibition of mitogen-activated protein kinase kinase or phosphatidylinositol 3-kinase counteracts the action of Ras to down-regulate p27 (16, 17). These findings strongly suggest that the receptor-Ras-(mitogen-activated protein kinase, phosphatidylinositol 3-kinase) signaling pathway plays an important role in p27 regulation. In the present study, we show that Grb2 and its alternatively spliced form, Grb3-3, bind to p27 in the cytoplasm and that the interaction between Grb2 and p27 is required for efficient degradation of p27. Our findings may, at least in part, explain why nuclear p27 is translocated to the cytoplasm before degradation and provide a novel pathway from the signal transduction machinery directly to the cell cycle regulator.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Recombinant Proteins and in Vitro Protein Binding Assay-- To construct the p27(PA) mutant, overlapping fragments of p27, introducing the relevant nucleotide changes, were made. The 3'-fragment was made by PCR1 using wild-type p27 cDNA as a template and the PA mutation primer (5'-C TAC TAC AGG GCC GCG CGC GCC GCC AAG AGC GCC TGC-3') and 3'-p27 primer (5'-AAGCTT CGT CTG GCG TCG AAG G-3'). The 5'-fragment was made using the same template but with the reverse PA mutation primer (5'-GCA GGC GCT CTT GGC GGC GCG CGC GGC CCT GTA GTA G-3') and 5'-p27 primer (5'-GGATCC ATG TCA AAC GTG AGA GTG T-3'). The overlapping PCR fragments were purified, mixed, and used as the template for the second PCR. The full-length p27(PA) mutant fragment was amplified by PCR using the 5'- and 3'-p27 primers introducing a 5' BamHI and a 3' HindIII site, respectively. cDNA fragments encoding p27 variants, Grb2, Grb3-3, and a variety of SH3-containing proteins were amplified by PCR using a pair of primers specific to each of them. The resulting PCR fragments were cloned, sequenced to confirm sequence integrity, and inserted into pGEX (Amersham Pharmacia Biotech) in frame with glutathione S-transferase (GST) and pBluescript. GST fusion proteins were expressed in bacteria and purified as described (18). Crude cell extracts containing recombinant mammalian cyclin D1-Cdk4 complex expressed in Sf9 cells by infection with baculovirus expression vectors were prepared as previously described (19). pBluescript plasmids containing cDNA were transcribed and translated in vitro in the presence of [35S]methionine using the TNT T7/T3 Coupled Reticulocyte Lysate Systems kit (Promega) according to the manufacturer's instructions. Binding was performed as described (5) in buffer containing 20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, and 0.5% Nonidet P-40, and the protein complexes were washed in the same buffer.

Cell Culture and High Efficiency Transfection-- NIH3T3 and COS7 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Grb2/Grb3-3 cDNA was inserted into the pFLAG-CMV-2 expression vector (Eastman Kodak Co.) in frame with a FLAG epitope. The expression vectors for p27 variants and Jab1 were previously described (5). Cells were transfected with vectors by a modified calcium phosphate-DNA precipitation method (20). The highest efficiency was obtained as described (5). Consistently, 50-80% of the transfected cells expressed exogenous proteins coded in the plasmid. Antisense oligonucleotides and controls directed to Grb2 have been designed and manufactured by Biognostik, Germany, and were directly added to the medium (final concentration 2 µM). Cells were cultured in the same medium for 3 days and harvested. Cell lysates were analyzed by immunoblotting using antibodies specific to Grb2, p27, and p21.

Protein Analyses-- Cells were harvested 24 h (for detection of the complex) and 48-72 h (for detection of p27 down-regulation) after transfection. Metabolic labeling, cell lysis, immunoprecipitation, gel electrophoresis, and immunoblotting were performed as described (5, 18, 19). Polyclonal antibodies to GST and p27 were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Mouse monoclonal antibodies to HA and FLAG peptide epitopes were obtained from Roche Molecular Biochemicals and Kodak, respectively.

Immunofluorescent Staining-- Cells were fixed in 3% paraformaldehyde, permeabilized in 0.5% Triton X-100, stained with anti-HA mouse monoclonal antibody (Roche Molecular Biochemicals), and incubated with Texas Red-linked anti-mouse IgG (Amersham Pharmacia Biotech). For determination of BrdU incorporation, cells stained with anti-HA rabbit polyclonal antibody (Babco) followed by Texas Red-linked antirabbit IgG (Amersham Pharmacia Biotech) were treated with 1.5 M HCl and stained with anti-bromodeoxyuridine mouse monoclonal antibody (Amersham Pharmacia Biotech) and fluorescein-linked anti-mouse IgG (Amersham Pharmacia Biotech). The cell samples were viewed by phase-contrast and/or fluorescence microscopy. More than 500 cells were examined for each transfectant.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Identification of Grb2 and Grb3-3 as New Interactors Specific to p27-- Using a yeast two-hybrid screen, we identified three kinds of cDNAs (5), all of which encode polypeptides capable of specifically interacting with the C-terminal domain of p27Kip1. We previously showed that one of them encodes Jab1/CSN5, which negatively regulates p27 by translocating it from the nucleus to the cytoplasm and subsequently inducing its degradation (5). The second class of cDNA contained the C-terminal SH3 domain of Grb2, which is well known to function as an adaptor molecule in the signal transduction pathway (14). To determine the specificity of the interaction between p27 and Grb2, we analyzed the capability of p27 to bind to other SH3-containing proteins. We selected from the data base several genes that encode proteins containing a SH3 domain closely related to the C-terminal SH3 domain of Grb2 (more than 40% identity), including STAM, SH3P8, SH3P13, and mNck-alpha (accession numbers are U43900, U58885, U58887, and AF043259, respectively) in addition to Grb2 and its alternatively spliced form, Grb3-3 (21). We cloned their coding sequences by PCR using a pair of primers specific to each of them, transcribed/translated them in vitro in the presence of [35S]methionine, and used these 35S-labeled proteins to assay in vitro the binding to GST and GST-fused p27 recombinant proteins preabsorbed onto glutathione beads. Fig. 1A shows that 35S-labeled Grb2 and Grb3-3 but not the others associated with GST-p27 fusion proteins in a test tube. The amounts of bound Grb2 and Grb3-3 were almost the same, and neither molecule bound to GST alone, indicating that the interaction between p27 and Grb proteins is specific and that Grb2 and Grb3-3 have equivalent binding capabilities at least in vitro.



View larger version (40K):
[in this window]
[in a new window]
 
Fig. 1.   Specific interaction of Grb2 with p27 in vitro. A, Grb2 and its variant Grb3-3 specifically interact with p27 in vitro. GST or GST-p27, immobilized on glutathione beads, was incubated with the in vitro translated 35S-labeled proteins shown at the top of the panel. Bound 35S-labeled proteins were detected by autoradiography. B, p27 mutants. C, in vitro interaction of GST-fused p27 deletion mutants with 35S-labeled Grb2 and Grb3-3. To confirm that equal amounts of GST fusion proteins were used, the results of immunoblotting using antibody to GST are also shown. D, a proline-rich sequence contained in p27 is required for interaction with Grb2/3-3. The binding assay was performed as in C. The results of anti-GST immunoblotting and a control binding assay with recombinant cyclin D1-Cdk4 complex (detected by anti-cyclin D1 immunoblot) are shown. E, Grb2 mutants. F, the C terminus SH3 domain of Grb2 is required for interaction with p27. The assay of the binding between GST-fused Grb2 variants and 35S-labeled p27 was performed as in C.

Among a variety of GST fusion proteins containing a portion of the p27 molecule (Fig. 1B), all that contained amino acids 89-96 bound to 35S-labeled, in vitro-transcribed/translated Grb2 and Grb3-3 proteins in a test tube (Fig. 1C). The N terminus deletion mutant, p27-(89-197), associated with Grb2/3-3 slightly weaker than other mutants, suggesting that amino acids adjacent to 89 are required for efficient interaction. The region of amino acids 89-96 is rich in proline residues and contains two overlapping SH3-binding motifs (PXXP) (14). Alteration of all of these 4 proline residues to alanine (RPPRPPK to RAARAAK) completely abolished the binding activity for Grb2/3-3, while this mutant, designated as p27(PA), retained the capability of interacting with cyclin D1-Cdk4 complexes (Fig. 1D), inhibiting the kinase activity of cyclin-Cdk complexes and inducing G1 arrest when overexpressed in mouse fibroblasts (data not shown, but see Fig. 4C). This proline-rich motif is unique to p27 and not found in sequences of other similar Cdk inhibitors, p21 and p57. In fact, we did not detect interaction between p21 and Grb2/Grb3-3 under these conditions in vitro (negative data not shown).

Grb3-3 consisting of two functional SH3 domains but lacking half of the SH2 domain (21) is able to bind to p27, indicating that the SH3 but not SH2 domain is involved in interaction with p27. To determine more precisely the binding domain within Grb proteins, we generated truncated mutants of Grb3-3, one containing the N terminus SH3 domain (SH3N) and the other the C terminus SH3 (SH3C) (Fig. 1E), and then tested them for activity to bind to 35S-labeled full-length p27 proteins in vitro (Fig. 1F). We found that the GST fusion protein containing the C terminus SH3 but not the N terminus SH3 interacted with p27. Thus, these results clearly indicate that p27 and Grb2/3-3 specifically interact with each other at least in vitro through the proline-rich motif and a specific SH3 domain.

Grb2 and Grb3-3 Bind to p27 in the Cytoplasm in Vivo-- In mouse fibroblasts, which express p27 and Grb2 but not Grb3-3 (data not shown), we were unable to detect a complex between endogenous p27 and Grb2; nor did we see any interaction between the two in COS cells overexpressing exogenous HA-tagged full-length p27 and FLAG-tagged Grb2 proteins (data not shown). This could be because the intracellular localization of the two proteins is different (p27 is in the nucleus and Grb2 in the cytoplasm) and because the intermediate p27-Grb2 complex exists only for a very limited time. We examined these possibilities by using p27 mutants. When we ectopically expressed FLAG-tagged Grb proteins together with the p27 mutant (p27(NES)) that localizes mainly in the cytoplasm because of the artificially fused NES sequence (5), we found that p27(NES) efficiently formed a complex with Grb2 and Grb3-3 in vivo (Fig. 2A). In addition, we detected very stable interaction between Grb2/Grb3-3 and another p27 mutant, p27-(1-151), which lacks the nuclear localization signal and remains in the cytoplasm (5) (data not shown). In another experiment, we observed a p27/Grb association when we used degradation-resistant p27 mutants (e.g. p27(T187A), p27-(1-186) (3-5)) (data not shown, but see Fig. 2C and below). With wild-type p27, Grb3-3, but not Grb2, formed a detectable amount of complex (Fig. 2B, seventh lane from the left). Thus, we conclude that (i) p27 binds to Grb proteins when it localizes in the cytoplasm, (ii) the p27/Grb2 interaction is very transient, and (iii) inhibition of Thr187 phosphorylation in p27 or disruption of SH2 function in Grb2 increases the stability of the complex (see below). In control experiments, we tested for p21 in lieu of p27 in normal NIH3T3 mouse fibroblasts and transfected COS cells and found that the interaction with Grb2/Grb3-3 was specific to p27 (negative data not shown).



View larger version (41K):
[in this window]
[in a new window]
 
Fig. 2.   Specific interaction of Grb proteins with cytoplasmic p27 in vivo. COS cells were transfected with the expression vectors shown at the top of the panels. Lysates from cells harvested 24 h post-transfection were directly analyzed by immunoblot with antibodies to HA and FLAG epitopes or subjected to immunoprecipitation (IP)/immunoblot analysis using the same antibodies. A, Grb2/3-3 form stable complexes with a p27 mutant containing artificial NES. B, binding of Grb3-3 with p27 was enhanced by ectopic expression of Jab1. C, both binding sites for Grb2 and Jab1 contained in p27 are required for p27/Grb2 interaction.

As for the factor that causes the cytoplasmic localization of p27, we focused on Jab1/CSN5, which directly binds to p27 and down-regulates the protein by translocating it from the nucleus to the cytoplasm (5). Since ectopic coexpression of HA-Jab1 (CSN5) induces down-regulation of wild-type p27 and its effect is prominent 48-72 h after transfection, we assayed for the complex formation 24 h after transfection, at which time p27 is not markedly down-regulated. Fig. 2B shows that coexpression of HA-Jab1 significantly increased the amount of complex formed between ectopic p27 and Grb3-3 proteins (seventh and eighth lanes from the left). Interestingly, upon immunoprecipitation with antibody specifically recognizing the C-terminal half of the p27 protein, Grb3-3 proteins were not coprecipitated. Since we did not detect Grb3-3 in anti-HA-immunoprecipitates from cells expressing HA-Jab1 and FLAG-Grb3-3, it seems likely that this anti-p27 antibody interfered with the formation of complex between p27 and Grb proteins, or, alternatively, HA-Jab1 may assist in increasing the stability of the p27-Grb protein complex. We detected interaction between wild-type p27 and Grb2 in the presence of ectopic HA-Jab1, but not in its absence (Fig. 2C). Mutation of the C terminus phosphorylation site (T187A), which renders p27 more stable (3-5), enhanced the complex formation, while mutation in the Grb2-binding site (p27(PA)) or deletion of the Jab1-binding domain (p27(Del 97-151)) abolished the interaction. The p27/Grb2/Jab1 interaction was completely disrupted in the presence of leptomycin B, a specific inhibitor of the NES/CRM1-dependent nuclear export (22) (data not shown). Ectopic Jab1/CSN5 did not induce complex formation between p21 and Grb2/3-3 (negative data not shown), confirming the specificity of the interaction. Thus, ectopic expression of Jab1 enables specific p27-Grb2 interaction by translocating p27 from the nucleus to the cytoplasm and by increasing the stability of the complex.

Grb2 Facilitates Down-regulation of p27 in Vivo-- We next examined the effect of Grb2 and Grb3-3 on p27 stability. Fig. 3A shows that ectopic p27 was relatively stable (open circle), and coexpression of Jab1/CSN5 markedly reduced its stability (closed circle) as previously reported (5). Additional coexpression of Grb2 further reduced the stability of p27 (open triangle), while coexpression of Grb3-3 blocked Jab1/CSN5-mediated down-regulation of p27 (closed triangle). Therefore, although only the SH3 domain is required for direct binding to p27, the integrity of the SH2 domain in Grb2 is important for induction of p27 down-regulation. The simplest interpretation is that the recruitment of a certain cellular protein, which most likely contains phosphorylated tyrosine residues, into the Grb2-p27-Jab1 complex would facilitate down-regulation of p27. However, Grb2 is well known to function in the signal transduction pathway (14), especially upstream of the Ras/Raf/mitogen-activated protein kinase pathway, the activation of which is reported to induce degradation of p27 (15-17). To analyze the possible involvement of the Ras signaling pathway in down-regulation of p27, we examined the effect of chemical inhibitors to mitogen-activated protein kinase kinase (PD98059 (PD); see Ref. 17) and phosphatidylinositol 3-kinase (wortmannin (WT); see Ref. 16) on the level of p27 in NIH3T3 cells transfected with HA-p27 together with Jab1/CSN5 and Grb2 (Fig. 3B). We found that Grb2 accelerated the degradation of p27 in the presence and absence of these inhibitors. These results strongly support our interpretation that Grb2 plays an important role in the regulation of p27 by the direct binding but not by activating the Ras signaling pathway.



View larger version (27K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of Grb proteins on the stability of p27. A, NIH3T3 cells were transfected with expression vectors (open circle, p27 alone; closed circle, p27 and Jab1; open triangle, p27, Jab1, and Grb2; closed triangle, p27, Jab1, and Grb3-3), pulse-labeled with [35S]methionine for 30 min at 48 h post-transfection and chased with excess cold methionine. At the indicated times, cells were collected, and the relative 35S in HA-p27 was measured. B, activation of the Ras signaling pathway is dispensable for accelerated degradation of p27 by Grb2. NIH3T3 cells were transfected with GFP together with p27, Jab1/CSN5, and Grb2 as indicated at the top, incubated for 6 h in the presence of chemical inhibitors (10 µM PD98059 (PD) and 2 µM wortmannin (WT)) at 48 h post-transfection, and harvested. Cell lysates containing the same amount of protein were analyzed by immunoblotting with antibodies specifically recognizing p27, Grb2, Jab1/CSN5, and GFP, respectively. We confirmed that PD98059 suppressed the activation of mitogen-activated protein kinase under these conditions. Wortmannin was used as described (16). DMSO, dimethyl sulfoxide.

Direct Binding of Grb2 Is Required for Down-regulation of p27-- To investigate the requirement of direct Grb binding in p27 down-regulation, we utilized the PA mutant of p27 (p27(PA)), which is unable to bind to Grb proteins due to amino acid substitutions in the SH3-binding motif but retains the capability of binding to other p27 binding proteins such as cyclin-Cdk complexes and Jab1 (Fig. 1D and data not shown). p27(PA) was located in the nucleus and transported to the cytoplasm in the presence of ectopic Jab1/CSN5 (Fig. 4A), indicating that the proline-to-alanine mutation did not affect nuclear import and Jab1/CSN5-mediated nuclear export of p27. The intensity of the nuclear staining was indistinguishable between the wild type and the PA mutant, but the signal of p27(PA) was much stronger than that of wild-type p27 in cells coexpressing Jab1/CSN5, implying that p27(PA) was not down-regulated in the presence of ectopic Jab1/CSN5. To directly examine this, we measured the half-life of these two p27 molecules in the presence and absence of ectopic Jab1 (Fig. 4B). Exogenous p27 was a relatively stable protein (open circle) and was induced to be degraded by coexpression of Jab1/CSN5 (closed circle). The PA mutant was kept stable whether Jab1/CSN5 was cotransfected or not (open and closed squares, respectively). In addition, although the ability of wild-type p27 to inhibit growth was partially rescued by Jab1/CSN5 coexpression, the PA mutant was quite resistant to the neutralizing effect of Jab1/CSN5 (Fig. 4C). These results, together with the observation that most of the cell lines we examined so far expressed Grb2 but not Grb3-3, indicate that the direct binding of Grb2 is required for cytoplasmic degradation of p27 but not for transportation of p27 from the nucleus to the cytoplasm.



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 4.   The integrity of the Grb2 binding site is required for Jab1-mediated down-regulation of p27. A, subcellular localization of the p27(PA) mutant in the presence and absence of Jab1. NIH3T3 cells were transfected with an HA-tagged p27(PA) mutant alone (top panels) or together with a Jab1 expression vector (bottom panels) and, at 48 h post-transfection, stained with antibody to an HA epitope followed by the Texas Red-tagged secondary antibody. The results obtained by phase-contrast (PC) and fluorescence microscopy (aHA) are shown. B, stability of wild-type and PA mutant p27 proteins in the presence and absence of ectopic Jab1. NIH3T3 cells were transfected with HA-p27 wild-type (circles) and PA mutant (squares) plasmids alone (open symbols) or with HA-Jab1 (closed symbols), and the relative 35S in HA-p27 was measured as in Fig. 3. C, p27(PA) is resistant to Jab1-mediated neutralization of the proliferation-inhibitory activity of p27. NIH3T3 cells were transfected with HA-p27 wild-type or PA mutant plasmids with or without FLAG-Jab1. After 48 h, cells were incubated with bromodeoxyuridine (BrdU) for 24 h and simultaneously stained with anti-HA and anti-bromodeoxyuridine antibodies. Percentages of bromodeoxyuridine-positive cells among HA-positive cells are shown.

Grb2 Is Required for Maintenance of Low Expression of p27 in Proliferating Fibroblasts-- To investigate the physiological importance of Grb2 in the regulation of p27 in vivo, we manipulated the expression of the Grb2 protein by antisense technology and examined the effect on p27 expression. The addition of the antisense oligonucleotides to the medium did not have any apparent effect on NIH3T3 fibroblasts during the first 24 h; however, at 3 days post-treatment, the rate of proliferation gradually slowed. Importantly, most cells neither exhibited a round morphology nor detached from the solid support during this period, indicating that few cells lost their viability due to the treatment with Grb2-specific antisense oligonucleotides. In these cells, the expression of Grb2 proteins was reduced to 36% compared with that in control cells. In contrast, p27 expression was 5 times higher than that in cells untreated or treated with random oligonucleotides. Importantly, Grb2 antisense oligonucleotides did not significantly alter the level of endogenous p21 proteins, indicating that the effect of Grb2 was specific to p27 (Fig. 5). These results demonstrate that Grb2 specifically functions upstream of p27 and is required for maintaining the low level of p27 protein.



View larger version (54K):
[in this window]
[in a new window]
 
Fig. 5.   Grb2 is required for down-regulation of p27 in proliferating fibroblasts. NIH3T3 cells (~10% confluence) were incubated in medium supplemented with 2 µM antisense oligonucleotides directed to Grb2 and control oligonucleotides and harvested after 3 days. Cell lysates containing the same amount of protein were analyzed by immunoblotting with antibodies specifically recognizing Grb2, p27, and p21.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Proteolytic down-regulation specifically linked to transportation from the nucleus to the cytoplasm is occasionally observed in the control of key regulators of cell proliferation, such as cyclin D1, p53, p27, and beta -catenin. Nuclear-cytoplasmic transportation and subsequent degradation of cyclin D1 is regulated by phosphorylation of a specific threonine residue (Thr286) by GSK-3beta kinase (23), which is a component of the signal transduction pathway. Ubiquitination and cytoplasmic transportation of p53 is mediated by MDM2 (24, 25), one of the p53-responsive gene products, thereby creating a negative feedback loop to make the effect of p53 temporal. Nuclear export of p27 is induced by Jab1/CSN5, which facilitates degradation of p27 in the cytoplasm. In this case, the cytoplasmic location of p27 alone is not sufficient for induction of p27 degradation (5), suggesting that Jab1/CSN5 has some role other than cytoplasmic shuttling of p27. Subcellular localization and turnover of beta -catenin is regulated by nuclear-cytoplasmic shuttling of APC (26). The question then arises as to why the protein needs to go to the cytoplasm before degradation. The simplest interpretation is that a certain factor compartmentalized to a specific area in the cytoplasm is required for degradation of these proteins, although no such factor has been identified yet. In the present study, we have found that Grb proteins specifically bind to p27 in the cytoplasm, which is required for efficient down-regulation of p27. Because Grb proteins function as an adaptor in the signal transduction pathway, one can easily speculate that Grb proteins mediate interaction between p27 and some unknown factor that may contain activity for ubiquitination or proteolysis. Grb2 accelerates degradation of p27 and Grb3-3 exhibits an opposite effect, suggesting that the SH2 domain is important presumably for recruitment of such a factor. Although we have no clues as to the molecular identity of the factor, it is feasible that tyrosine phosphorylation of the factor by the growth factor receptor triggers association with the p27-Grb2 complex.

p27 is subject to multiple forms of regulation (1, 2). It is transcriptionally activated by the CBP coactivator in response to retinoic acid treatment (27) and by the Ah receptor (28). Translational control of p27 expression is also reported (29-31). However, because the level of p27 protein fluctuates during the cell cycle (high in G0/G1 and low in S, G2, and M), while the level of p27 mRNA is constant (29, 30), the main regulatory mechanism for p27 seems to be post-translational, mostly due to the activation and inactivation of substrate-specific and cell cycle-dependent proteolysis. Degradation of p27 has been reported to involve phosphorylation of Thr187 by cyclin E-Cdk2 complex (3, 4), nuclear export induced by Jab1/CSN5 (5), ubiquitination mediated by the ubiquitin ligase SCFSKP2 complex (6-8), and proteolysis by the 26 S proteasome. However, the precise biochemical link between these events and the biochemical reaction that initiates p27 degradation remains to be clarified. Nullification of Skp2, an F-box-containing subunit of the SCF ubiquitin ligase, results in up-regulation of p27 (32). Introduction of the dominant negative form of Jab1 increases levels of p27 expression in proliferating mouse fibroblasts.2 Therefore, these two pathways seem to significantly participate in the regulation of p27 in vivo. But we have not obtained any evidence that p27 exported from the nucleus by Jab1/CSN5 is ubiquitinated by SCFSKP2 in the cytoplasm. This may suggest that these two pathways are independent. Although experiments using Skp2-/- cells need to be performed to clarify this issue, it is feasible that the down-regulation of p27 occurs in several steps. Jab1/CSN5 and Grb2 may be involved in the down-regulation during early to mid-G1, and the cyclin E-Cdk2-SCFSkp2 pathway may govern the late G1 to S phase event.

Cancers with low p27 protein expression are reported to be well correlated with poor prognosis (33-35). This finding was originally made in breast and colorectal carcinomas and now is the case for a wide variety of human tumors. Since the p27 gene is rarely altered in human cancers, the genetic target for malignant transformation seems to be the gene functioning upstream of p27. Overexpression of the SKP2 gene is occasionally observed in transformed cells (36) but is not necessarily correlated with low expression of p27. So far, no alteration of Jab1/CSN5 expression has been reported, but because other components of the COP9 signalosome complex are capable of down-regulating p27,2 it is necessary to investigate whether any other CSN is involved in human cancers. In addition, our results suggest that the possible role of Grb2 and its associated proteins in tumorigenesis has to be reevaluated in terms not only of activation of the signal transduction pathway leading to Ras activation but also of direct involvement in control of the key cell cycle regulator.


    ACKNOWLEDGEMENTS

We thank Drs. C. J. Sherr and J. Fujisawa for the plasmids and baculoviruses.


    FOOTNOTES

* This work was supported by Grants-in-Aid for Scientific Research and for Cancer Research from the Ministry of Education, Science, and Culture of Japan and the Special Coordination Funds of the Ministry of Education, Culture, Sports, Science, and Technology of the Japanese government.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by Research Fellowships of the Japan Society for the Promotion of Science for Young Scientists.

§ To whom correspondence should be addressed. Tel.: 81-743-72-5541; Fax: 81-743-72-5549; E-mail: jkata@bs.aist-nara.ac.jp.

Published, JBC Papers in Press, January 22, 2001, DOI 10.1074/jbc.M010811200

2 K. Tomoda, Y. Arata, T. Tanaka, N. Yoneda-Kato, and J. Kato, unpublished observation.


    ABBREVIATIONS

The abbreviations used are: PCR, polymerase chain reaction; HA, hemagglutinin; SH2 and SH3, Src homology domain 2 and 3, respectively; GST, glutathione S-transferase.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Sgambato, A., Cittadini, A., Faraglia, B., and Weinstein, I. B. (2000) J. Cell. Physiol. 183, 18-27[CrossRef][Medline] [Order article via Infotrieve]
2. Slingerland, J., and Pagano, M. (2000) J. Cell. Physiol. 183, 10-17[CrossRef][Medline] [Order article via Infotrieve]
3. Sheaff, R. J., Groudine, M., Gordon, M., Roberts, J. M., and Clurman, B. E. (1997) Genes Dev. 11, 1464-1478[Abstract]
4. Vlach, J., Hennecke, S., and Amati, B. (1997) EMBO J. 16, 5334-5344[Abstract/Free Full Text]
5. Tomoda, K., Kubota, Y., and Kato, J. (1999) Nature 398, 160-165[CrossRef][Medline] [Order article via Infotrieve]
6. Carrano, A. C., Eytan, E., Hershko, A., and Pagano, M. (1999) Nat. Cell Biol. 1, 193-199[CrossRef][Medline] [Order article via Infotrieve]
7. Sutterluty, H., Chatelain, E., Marti, A., Wirbelauer, C., Senften, M., Muller, U., and Krek, W. (1999) Nat. Cell Biol. 1, 207-214[CrossRef][Medline] [Order article via Infotrieve]
8. Tsvetkov, L. M., Yeh, K. H., Lee, S. J., Sun, H., and Zhang, H. (1999) Curr. Biol. 9, 661-664[CrossRef][Medline] [Order article via Infotrieve]
9. Claret, F. X., Hibi, M., Dhut, S., Toda, T., and Karin, M. (1996) Nature 383, 453-457[CrossRef][Medline] [Order article via Infotrieve]
10. Wei, N., and Deng, X. W. (1999) Trends Genet. 15, 98-103[CrossRef][Medline] [Order article via Infotrieve]
11. Deng, X. W., Dubiel, W., Wei, N., Hofmann, K., Mundt, K., Colicelli, J., Kato, J., Naumann, M., Segal, D., Seeger, M., Carr, A., Glickman, M., and Chamovitz, D. A. (2000) Trends Genet. 16, 202-203[CrossRef][Medline] [Order article via Infotrieve]
12. Freilich, S., Oron, E., Kapp, Y., Nevo-Caspi, Y., Orgad, S., Segal, D., and Chamovitz, D. A. (1999) Curr. Biol. 9, 1187-1190[CrossRef][Medline] [Order article via Infotrieve]
13. Schlessinger, J. (2000) Cell 103, 211-225[Medline] [Order article via Infotrieve]
14. Birge, R. B., Knudsen, B. S., Besser, D., and Hanafusa, H. (1996) Genes Cells 1, 595-613[Abstract/Free Full Text]
15. Aktas, H., Cai, H., and Cooper, G. M. (1997) Mol. Cell. Biol. 17, 3850-3857[Abstract]
16. Takuwa, N., and Takuwa, Y. (1997) Mol. Cell. Biol. 17, 5348-5358[Abstract]
17. Kawada, M., Yamagoe, S., Murakami, Y., Suzuki, K., Mizuno, S., and Uehara, Y. (1997) Oncogene 15, 629-637[CrossRef][Medline] [Order article via Infotrieve]
18. Akamatsu, E., Tanaka, T., and Kato, J. (1998) J. Biol. Chem. 273, 16494-16500[Abstract/Free Full Text]
19. Kato, J., Matsushime, H., Hiebert, S. W., Ewen, M. E., and Sherr, C. J. (1993) Genes Dev. 7, 331-342[Abstract]
20. Chen, C., and Okayama, H. (1987) Mol. Cell. Biol. 7, 2745-2752[Medline] [Order article via Infotrieve]
21. Fath, I., Schweighoffer, F., Rey, I., Multon, M. C., Boiziau, J., Duchesne, M., and Tocque, B. (1994) Science 264, 971-974[Medline] [Order article via Infotrieve]
22. Nishi, K., Yoshida, M., Fujiwara, D., Nishikawa, M., Horinouchi, S., and Beppu, T. (1994) J. Biol. Chem. 269, 6320-6324[Abstract/Free Full Text]
23. Diehl, J. A., Cheng, M., Roussel, M. F., and Sherr, C. J. (1998) Genes Dev. 12, 3499-3511[Abstract/Free Full Text]
24. Levine, A. J. (1997) Cell 88, 323-331[Medline] [Order article via Infotrieve]
25. Giaccia, A. J., and Kastan, M. B. (1998) Genes Dev. 12, 2973-2983[Free Full Text]
26. Henderson, B. R. (2000) Nat. Cell Biol. 2, 653-660[CrossRef][Medline] [Order article via Infotrieve]
27. Kawasaki, H., Eckner, R., Yao, T.-P., Taira, K., Chiu, R., Livingston, D. M., and Yokoyama, K. K. (1998) Nature 393, 284-289[CrossRef][Medline] [Order article via Infotrieve]
28. Kolluri, S. K., Weiss, C., Koff, A., and Gottlicher, M. (1999) Genes Dev. 13, 1742-1753[Abstract/Free Full Text]
29. Hengst, L., and Reed, S. I. (1996) Science 271, 1861-1864[Abstract]
30. Millard, S. S., Yan, J. S., Nguyen, H., Pagano, M., Kiyokawa, H., and Koff, A. (1997) J. Biol. Chem. 272, 7093-7098[Abstract/Free Full Text]
31. Millard, S. S., Vidal, A., Markus, M., and Koff, A. (2000) Mol. Cell. Biol. 20, 5947-5959[Abstract/Free Full Text]
32. Nakayama, K., Nagahama, H., Minamishima, Y. A., Matsumoto, M., Nakamichi, I., Kitagawa, K., Shirane, M., Tsunematsu, R., Tsukiyama, T., Ishida, N., Kitagawa, M., Nakayama, K., and Hatakeyama, S. (2000) EMBO J. 19, 2069-2081[Abstract/Free Full Text]
33. Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R., and Roberts, J. M. (1997) Nat. Med. 3, 222-225[Medline] [Order article via Infotrieve]
34. Catzavelos, C., Bhattacharya, N., Ung, Y. C., Wilson, J. A., Roncari, L., Sandhu, C., Shaw, P., Yeger, H., Morava-Protzner, I., Kapusta, L., Franssen, E., Pritchard, K. I., and Slingerland, J. M. (1997) Nat. Med. 3, 227-230[Medline] [Order article via Infotrieve]
35. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Jessup, J. M., and Pagano, M. (1997) Nat. Med. 3, 231-234[Medline] [Order article via Infotrieve]
36. Zhang, H., Kobayashi, R., Galaktionov, K., and Beach, D. (1995) Cell 82, 915-925[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.